ESR1 and breast carcinoma: Interestingly, NFκB activation does not only protect against loss of ERα function, but also promotes growth of Her2-positive breast cancer cells in the presence of a Her2 inhibitor [48] suggesting that NFκB activation is a general option for breast cancer cells to survive under conditions where the major growth-permitting pathway is blocked.